Patient characteristics by translocation partner
| Characteristic . | KMT2A t(9;11) . | KMT2A t(10;11) . | KMT2A t(6;11) . | KMT2A t(11;19) . | KMT2A Other . | KMT2A undefined . |
|---|---|---|---|---|---|---|
| Patients, n | 112 | 28 | 41 | 62 | 47 | 136 |
| Centers, n | 63 | 24 | 31 | 39 | 37 | 64 |
| Patient characteristics | ||||||
| Patient age at HCT, n (%) | ||||||
| Median (min-max) | 45.8 (20.1-69.9) | 34.3 (18.4-67.4) | 45.5 (18.3-62.7) | 45.2 (18.4-69.8) | 53.7 (18.3-69.3) | 49.6 (18.2-70) |
| 18-29 | 18 (16) | 9 (32) | 7 (17) | 9 (15) | 5 (11) | 24 (18) |
| 30-39 | 19 (17) | 9 (32) | 7 (17) | 12 (19) | 6 (13) | 17 (13) |
| 40-49 | 36 (32) | 5 (18) | 13 (32) | 17 (27) | 7 (15) | 30 (22) |
| 50-59 | 26 (23) | 3 (11) | 13 (32) | 18 (29) | 19 (40) | 39 (29) |
| 60-69 | 13 (12) | 2 (7) | 1 (2) | 6 (10) | 10 (21) | 26 (19) |
| Sex, n (%) | ||||||
| Male | 43 (38) | 8 (29) | 11 (27) | 23 (37) | 25 (53) | 69 (51) |
| Female | 69 (62) | 20 (71) | 30 (73) | 39 (63) | 22 (47) | 67 (49) |
| Karnofsky score, n (%) | ||||||
| <90 | 36 (32) | 12 (43) | 13 (32) | 23 (37) | 17 (36) | 35 (26) |
| ≥90 | 73 (65) | 16 (57) | 27 (66) | 37 (60) | 29 (62) | 98 (72) |
| Missing | 3 (3) | 0 | 1 (2) | 2 (3) | 1 (2) | 3 (2) |
| HCT-CI, n (%) | ||||||
| 0 | 15 (13) | 9 (32) | 9 (22) | 11 (18) | 8 (17) | 37 (27) |
| 1-2 | 29 (26) | 6 (21) | 14 (34) | 21 (34) | 13 (28) | 33 (24) |
| 3+ | 59 (53) | 8 (29) | 14 (34) | 24 (39) | 20 (43) | 57 (42) |
| Missing | 9 (8) | 5 (18) | 4 (10) | 6 (10) | 6 (13) | 9 (7) |
| Recipient CMV serostatus, n (%) | ||||||
| Negative | 41 (37) | 8 (29) | 10 (24) | 27 (44) | 17 (36) | 44 (32) |
| Positive | 71 (63) | 20 (71) | 31 (76) | 35 (56) | 29 (62) | 91 (67) |
| Missing | 0 | 0 | 0 | 0 | 1 (2) | 1 (1) |
| Disease characteristics | ||||||
| Type of AML, n (%) | ||||||
| tAML | 38 (34) | 3 (11) | 4 (10) | 9 (15) | 10 (21) | 24 (18) |
| Antecedent MDS | 1 (1) | 3 (11) | 1 (2) | 6 (10) | 6 (13) | 10 (7) |
| De novo disease | 73 (65) | 22 (79) | 36 (88) | 47 (76) | 31 (66) | 102 (75) |
| Prior disease, n (%) | ||||||
| AML, not therapy related | 74 (66) | 25 (89) | 37 (90) | 53 (85) | 37 (79) | 112 (82) |
| HD | 2 (2) | 0 | 0 | 0 (0) | 0 (0) | 3 (2) |
| NHL | 5 (4) | 0 | 1 (2) | 2 (3) | 3 (6) | 3 (2) |
| Breast cancer | 24 (21) | 1 (4) | 3 (7) | 3 (5) | 6 (13) | 11 (8) |
| Solid tumor | 2 (2) | 0 | 0 | 3 (5) | 0 (0) | 4 (3) |
| Other | 4 (4) | 2 (7) | 0 | 1 (2) | 1 (2) | 3 (2) |
| Missing | 1 (1) | 0 | 0 | 0 (0) | 0 (0) | 0 (0) |
| Therapy for previous disease, n (%) | ||||||
| AML, not therapy related | 74 (66) | 25 (89) | 37 (90) | 53 (85) | 37 (79) | 112 (82) |
| Chemotherapy | 19 (17) | 2 (7) | 2 (5) | 2 (3) | 5 (11) | 13 (10) |
| Chemotherapy + radiation | 16 (14) | 1 (4) | 2 (5) | 6 (10) | 4 (9) | 11 (8) |
| Radiation alone | 2 (2) | 0 | 0 | 0 (0) | 0 (0) | 0 (0) |
| Other | 1 (1) | 0 | 0 | 1 (2) | 1 (2) | 0 (0) |
| Extramedullary disease at diagnosis, n (%) | ||||||
| No | 101 (90) | 25 (89) | 36 (88) | 59 (95) | 44 (94) | 129 (95) |
| Yes | 8 (7) | 2 (7) | 3 (7) | 3 (5) | 3 (6) | 4 (3) |
| Missing | 3 (3) | 1 (4) | 2 (5) | 0 | 0 | 3 (2) |
| WBC count at diagnosis, AML (x 109/L), n (%) | ||||||
| Median (min-max) | 7.4 (0.6-432) | 7.1 (0.8-128) | 37.3 (1-284) | 17.8 (0.7-270) | 12.3 (0.4-228) | 7.2 (0.1-318.2) |
| ≤ 10 | 57 (51) | 13 (46) | 13 (32) | 24 (39) | 19 (40) | 65 (48) |
| 10-100 | 38 (34) | 10 (36) | 16 (39) | 27 (44) | 23 (49) | 39 (29) |
| > 100 | 7 (6) | 2 (7) | 8 (20) | 5 (8) | 3 (6) | 16 (12) |
| Missing | 10 (9) | 3 (11) | 4 (10) | 6 (10) | 2 (4) | 16 (12) |
| Time to achieve CR1 (weeks), n (%) | ||||||
| Median (min-max) | 5 (1.6-20.4) | 6.8 (1.9-36.4) | 7.1 (2-18.6) | 5 (2-30) | 6.7 (2-45.6) | 5.6 (0.4-29.9) |
| ≤4 wk | 31 (28) | 6 (21) | 5 (12) | 18 (29) | 8 (17) | 35 (26) |
| 4-8 wk | 54 (48) | 11 (39) | 20 (49) | 31 (50) | 18 (38) | 65 (48) |
| >8 wk | 26 (23) | 11 (39) | 15 (37) | 13 (21) | 21 (45) | 35 (26) |
| Missing | 1 (1) | 0 | 1 (2) | 0 | 0 | 1 (1) |
| Time from CR1 to HCT (months), n (%) | ||||||
| Median (min-max) | 3 (0.3-16.8) | 2.9 (0.7-8.7) | 2.4 (0.5-7.3) | 2.6 (0.5-7.6) | 2.5 (0.5-11.1) | 2.8 (0.4-12.8) |
| <3 mo | 56 (50) | 16 (57) | 26 (63) | 35 (56) | 30 (64) | 76 (56) |
| 3-6 mo | 41 (37) | 9 (32) | 9 (22) | 25 (40) | 13 (28) | 49 (36) |
| >6 mo | 14 (13) | 3 (11) | 5 (12) | 2 (3) | 4 (9) | 10 (7) |
| Missing | 1 (1) | 0 | 1 (2) | 0 | 0 | 1 (1) |
| Number of courses of induction for CR1 cases, n (%) | ||||||
| 1 | 85 (76) | 21 (75) | 27 (66) | 47 (76) | 33 (70) | 99 (73) |
| 2 | 12 (11) | 2 (7) | 10 (24) | 6 (10) | 8 (17) | 26 (19) |
| 3 | 5 (4) | 0 | 1 (2) | 3 (5) | 1 (2) | 3 (2) |
| Missing | 10 (9) | 5 (18) | 3 (7) | 6 (10) | 5 (11) | 8 (6) |
| MRD at time of HCT, n (%) | ||||||
| Negative | 82 (73) | 18 (64) | 28 (68) | 38 (61) | 33 (70) | 97 (71) |
| Positive | 13 (12) | 4 (14) | 6 (15) | 12 (19) | 8 (17) | 26 (19) |
| Missing | 17 (15) | 6 (21) | 7 (17) | 12 (19) | 6 (13) | 13 (10) |
| Transplant characteristics | ||||||
| Donor type, n (%) | ||||||
| HLA-identical sibling | 23 (21) | 9 (32) | 13 (32) | 18 (29) | 9 (19) | 35 (26) |
| Haplo-identical | 9 (8) | 0 | 0 | 6 (10) | 2 (4) | 6 (4) |
| Other related | 4 (4) | 0 | 0 | 1 (2) | 0 | 4 (3) |
| Well-matched unrelated (8/8) | 43 (38) | 10 (36) | 16 (39) | 26 (42) | 23 (49) | 55 (40) |
| Partially matched unrelated (7/8) | 10 (9) | 2 (7) | 6 (15) | 3 (5) | 5 (11) | 13 (10) |
| Cord blood | 23 (21) | 7 (25) | 6 (15) | 8 (13) | 8 (17) | 23 (17) |
| Conditioning intensity, n (%) | ||||||
| MA-TBI | 23 (21) | 12 (43) | 12 (29) | 19 (31) | 11 (23) | 28 (21) |
| MA-Chemo | 54 (48) | 11 (39) | 15 (37) | 25 (40) | 16 (34) | 62 (46) |
| RIC/NMA | 32 (29) | 5 (18) | 13 (32) | 16 (26) | 20 (43) | 43 (32) |
| Under review | 3 (3) | 0 | 1 (2) | 2 (3) | 0 | 3 (2) |
| GVHD prophylaxis, n (%) | ||||||
| Post tx-cy | 17 (15) | 0 | 3 (7) | 6 (10) | 2 (4) | 7 (5) |
| Tac based | 71 (63) | 16 (57) | 31 (76) | 43 (69) | 36 (77) | 98 (72) |
| CSA based | 21 (19) | 11 (39) | 6 (15) | 13 (21) | 9 (19) | 29 (21) |
| Other | 1 (1) | 0 | 0 | 0 | 0 | 1 (1) |
| Missing | 2 (2) | 1 (4) | 1 (2) | 0 | 0 | 1 (1) |
| ATG/Campath, n (%) | ||||||
| ATG alone | 18 (16) | 8 (29) | 8 (20) | 9 (15) | 11 (23) | 36 (26) |
| Alemtuzumab alone | 3 (3) | 0 | 0 | 1 (2) | 0 | 5 (4) |
| No ATG or alemtuzumab | 91 (81) | 19 (68) | 33 (80) | 52 (84) | 36 (77) | 95 (70) |
| Missing | 0 | 1 (4) | 0 | 0 | 0 | 0 |
| Graft type, n (%) | ||||||
| Bone marrow | 26 (23) | 3 (11) | 6 (15) | 11 (18) | 7 (15) | 27 (20) |
| Peripheral blood | 63 (56) | 18 (64) | 29 (71) | 43 (69) | 32 (68) | 86 (63) |
| Cord blood | 23 (21) | 7 (25) | 6 (15) | 8 (13) | 8 (17) | 23 (17) |
| Year of transplant, n (%) | ||||||
| 2007 | 9 (8) | 5 (18) | 4 (10) | 6 (10) | 6 (13) | 9 (7) |
| 2008 | 14 (13) | 3 (11) | 9 (22) | 7 (11) | 6 (13) | 18 (13) |
| 2009 | 13 (12) | 7 (25) | 5 (12) | 6 (10) | 7 (15) | 18 (13) |
| 2010 | 13 (12) | 2 (7) | 4 (10) | 10 (16) | 6 (13) | 25 (18) |
| 2011 | 6 (5) | 1 (4) | 2 (5) | 1 (2) | 1 (2) | 5 (4) |
| 2012 | 5 (4) | 1 (4) | 3 (7) | 4 (6) | 2 (4) | 7 (5) |
| 2013 | 9 (8) | 3 (11) | 1 (2) | 7 (11) | 4 (9) | 18 (13) |
| 2014 | 23 (21) | 1 (4) | 4 (10) | 9 (15) | 8 (17) | 11 (8) |
| 2015 | 11 (10) | 2 (7) | 2 (5) | 7 (11) | 5 (11) | 11 (8) |
| 2016 | 9 (8) | 3 (11) | 7 (17) | 5 (8) | 2 (4) | 14 (10) |
| Follow-up, median (min-max) | 49.24 (6.12-126.41) | 52.57 (3.36-100.07) | 55.89 (3.42-90) | 47.4 (3.32-99.28) | 71.45 (3.49-97.86) | 48.19 (5.92-116.18) |
| Characteristic . | KMT2A t(9;11) . | KMT2A t(10;11) . | KMT2A t(6;11) . | KMT2A t(11;19) . | KMT2A Other . | KMT2A undefined . |
|---|---|---|---|---|---|---|
| Patients, n | 112 | 28 | 41 | 62 | 47 | 136 |
| Centers, n | 63 | 24 | 31 | 39 | 37 | 64 |
| Patient characteristics | ||||||
| Patient age at HCT, n (%) | ||||||
| Median (min-max) | 45.8 (20.1-69.9) | 34.3 (18.4-67.4) | 45.5 (18.3-62.7) | 45.2 (18.4-69.8) | 53.7 (18.3-69.3) | 49.6 (18.2-70) |
| 18-29 | 18 (16) | 9 (32) | 7 (17) | 9 (15) | 5 (11) | 24 (18) |
| 30-39 | 19 (17) | 9 (32) | 7 (17) | 12 (19) | 6 (13) | 17 (13) |
| 40-49 | 36 (32) | 5 (18) | 13 (32) | 17 (27) | 7 (15) | 30 (22) |
| 50-59 | 26 (23) | 3 (11) | 13 (32) | 18 (29) | 19 (40) | 39 (29) |
| 60-69 | 13 (12) | 2 (7) | 1 (2) | 6 (10) | 10 (21) | 26 (19) |
| Sex, n (%) | ||||||
| Male | 43 (38) | 8 (29) | 11 (27) | 23 (37) | 25 (53) | 69 (51) |
| Female | 69 (62) | 20 (71) | 30 (73) | 39 (63) | 22 (47) | 67 (49) |
| Karnofsky score, n (%) | ||||||
| <90 | 36 (32) | 12 (43) | 13 (32) | 23 (37) | 17 (36) | 35 (26) |
| ≥90 | 73 (65) | 16 (57) | 27 (66) | 37 (60) | 29 (62) | 98 (72) |
| Missing | 3 (3) | 0 | 1 (2) | 2 (3) | 1 (2) | 3 (2) |
| HCT-CI, n (%) | ||||||
| 0 | 15 (13) | 9 (32) | 9 (22) | 11 (18) | 8 (17) | 37 (27) |
| 1-2 | 29 (26) | 6 (21) | 14 (34) | 21 (34) | 13 (28) | 33 (24) |
| 3+ | 59 (53) | 8 (29) | 14 (34) | 24 (39) | 20 (43) | 57 (42) |
| Missing | 9 (8) | 5 (18) | 4 (10) | 6 (10) | 6 (13) | 9 (7) |
| Recipient CMV serostatus, n (%) | ||||||
| Negative | 41 (37) | 8 (29) | 10 (24) | 27 (44) | 17 (36) | 44 (32) |
| Positive | 71 (63) | 20 (71) | 31 (76) | 35 (56) | 29 (62) | 91 (67) |
| Missing | 0 | 0 | 0 | 0 | 1 (2) | 1 (1) |
| Disease characteristics | ||||||
| Type of AML, n (%) | ||||||
| tAML | 38 (34) | 3 (11) | 4 (10) | 9 (15) | 10 (21) | 24 (18) |
| Antecedent MDS | 1 (1) | 3 (11) | 1 (2) | 6 (10) | 6 (13) | 10 (7) |
| De novo disease | 73 (65) | 22 (79) | 36 (88) | 47 (76) | 31 (66) | 102 (75) |
| Prior disease, n (%) | ||||||
| AML, not therapy related | 74 (66) | 25 (89) | 37 (90) | 53 (85) | 37 (79) | 112 (82) |
| HD | 2 (2) | 0 | 0 | 0 (0) | 0 (0) | 3 (2) |
| NHL | 5 (4) | 0 | 1 (2) | 2 (3) | 3 (6) | 3 (2) |
| Breast cancer | 24 (21) | 1 (4) | 3 (7) | 3 (5) | 6 (13) | 11 (8) |
| Solid tumor | 2 (2) | 0 | 0 | 3 (5) | 0 (0) | 4 (3) |
| Other | 4 (4) | 2 (7) | 0 | 1 (2) | 1 (2) | 3 (2) |
| Missing | 1 (1) | 0 | 0 | 0 (0) | 0 (0) | 0 (0) |
| Therapy for previous disease, n (%) | ||||||
| AML, not therapy related | 74 (66) | 25 (89) | 37 (90) | 53 (85) | 37 (79) | 112 (82) |
| Chemotherapy | 19 (17) | 2 (7) | 2 (5) | 2 (3) | 5 (11) | 13 (10) |
| Chemotherapy + radiation | 16 (14) | 1 (4) | 2 (5) | 6 (10) | 4 (9) | 11 (8) |
| Radiation alone | 2 (2) | 0 | 0 | 0 (0) | 0 (0) | 0 (0) |
| Other | 1 (1) | 0 | 0 | 1 (2) | 1 (2) | 0 (0) |
| Extramedullary disease at diagnosis, n (%) | ||||||
| No | 101 (90) | 25 (89) | 36 (88) | 59 (95) | 44 (94) | 129 (95) |
| Yes | 8 (7) | 2 (7) | 3 (7) | 3 (5) | 3 (6) | 4 (3) |
| Missing | 3 (3) | 1 (4) | 2 (5) | 0 | 0 | 3 (2) |
| WBC count at diagnosis, AML (x 109/L), n (%) | ||||||
| Median (min-max) | 7.4 (0.6-432) | 7.1 (0.8-128) | 37.3 (1-284) | 17.8 (0.7-270) | 12.3 (0.4-228) | 7.2 (0.1-318.2) |
| ≤ 10 | 57 (51) | 13 (46) | 13 (32) | 24 (39) | 19 (40) | 65 (48) |
| 10-100 | 38 (34) | 10 (36) | 16 (39) | 27 (44) | 23 (49) | 39 (29) |
| > 100 | 7 (6) | 2 (7) | 8 (20) | 5 (8) | 3 (6) | 16 (12) |
| Missing | 10 (9) | 3 (11) | 4 (10) | 6 (10) | 2 (4) | 16 (12) |
| Time to achieve CR1 (weeks), n (%) | ||||||
| Median (min-max) | 5 (1.6-20.4) | 6.8 (1.9-36.4) | 7.1 (2-18.6) | 5 (2-30) | 6.7 (2-45.6) | 5.6 (0.4-29.9) |
| ≤4 wk | 31 (28) | 6 (21) | 5 (12) | 18 (29) | 8 (17) | 35 (26) |
| 4-8 wk | 54 (48) | 11 (39) | 20 (49) | 31 (50) | 18 (38) | 65 (48) |
| >8 wk | 26 (23) | 11 (39) | 15 (37) | 13 (21) | 21 (45) | 35 (26) |
| Missing | 1 (1) | 0 | 1 (2) | 0 | 0 | 1 (1) |
| Time from CR1 to HCT (months), n (%) | ||||||
| Median (min-max) | 3 (0.3-16.8) | 2.9 (0.7-8.7) | 2.4 (0.5-7.3) | 2.6 (0.5-7.6) | 2.5 (0.5-11.1) | 2.8 (0.4-12.8) |
| <3 mo | 56 (50) | 16 (57) | 26 (63) | 35 (56) | 30 (64) | 76 (56) |
| 3-6 mo | 41 (37) | 9 (32) | 9 (22) | 25 (40) | 13 (28) | 49 (36) |
| >6 mo | 14 (13) | 3 (11) | 5 (12) | 2 (3) | 4 (9) | 10 (7) |
| Missing | 1 (1) | 0 | 1 (2) | 0 | 0 | 1 (1) |
| Number of courses of induction for CR1 cases, n (%) | ||||||
| 1 | 85 (76) | 21 (75) | 27 (66) | 47 (76) | 33 (70) | 99 (73) |
| 2 | 12 (11) | 2 (7) | 10 (24) | 6 (10) | 8 (17) | 26 (19) |
| 3 | 5 (4) | 0 | 1 (2) | 3 (5) | 1 (2) | 3 (2) |
| Missing | 10 (9) | 5 (18) | 3 (7) | 6 (10) | 5 (11) | 8 (6) |
| MRD at time of HCT, n (%) | ||||||
| Negative | 82 (73) | 18 (64) | 28 (68) | 38 (61) | 33 (70) | 97 (71) |
| Positive | 13 (12) | 4 (14) | 6 (15) | 12 (19) | 8 (17) | 26 (19) |
| Missing | 17 (15) | 6 (21) | 7 (17) | 12 (19) | 6 (13) | 13 (10) |
| Transplant characteristics | ||||||
| Donor type, n (%) | ||||||
| HLA-identical sibling | 23 (21) | 9 (32) | 13 (32) | 18 (29) | 9 (19) | 35 (26) |
| Haplo-identical | 9 (8) | 0 | 0 | 6 (10) | 2 (4) | 6 (4) |
| Other related | 4 (4) | 0 | 0 | 1 (2) | 0 | 4 (3) |
| Well-matched unrelated (8/8) | 43 (38) | 10 (36) | 16 (39) | 26 (42) | 23 (49) | 55 (40) |
| Partially matched unrelated (7/8) | 10 (9) | 2 (7) | 6 (15) | 3 (5) | 5 (11) | 13 (10) |
| Cord blood | 23 (21) | 7 (25) | 6 (15) | 8 (13) | 8 (17) | 23 (17) |
| Conditioning intensity, n (%) | ||||||
| MA-TBI | 23 (21) | 12 (43) | 12 (29) | 19 (31) | 11 (23) | 28 (21) |
| MA-Chemo | 54 (48) | 11 (39) | 15 (37) | 25 (40) | 16 (34) | 62 (46) |
| RIC/NMA | 32 (29) | 5 (18) | 13 (32) | 16 (26) | 20 (43) | 43 (32) |
| Under review | 3 (3) | 0 | 1 (2) | 2 (3) | 0 | 3 (2) |
| GVHD prophylaxis, n (%) | ||||||
| Post tx-cy | 17 (15) | 0 | 3 (7) | 6 (10) | 2 (4) | 7 (5) |
| Tac based | 71 (63) | 16 (57) | 31 (76) | 43 (69) | 36 (77) | 98 (72) |
| CSA based | 21 (19) | 11 (39) | 6 (15) | 13 (21) | 9 (19) | 29 (21) |
| Other | 1 (1) | 0 | 0 | 0 | 0 | 1 (1) |
| Missing | 2 (2) | 1 (4) | 1 (2) | 0 | 0 | 1 (1) |
| ATG/Campath, n (%) | ||||||
| ATG alone | 18 (16) | 8 (29) | 8 (20) | 9 (15) | 11 (23) | 36 (26) |
| Alemtuzumab alone | 3 (3) | 0 | 0 | 1 (2) | 0 | 5 (4) |
| No ATG or alemtuzumab | 91 (81) | 19 (68) | 33 (80) | 52 (84) | 36 (77) | 95 (70) |
| Missing | 0 | 1 (4) | 0 | 0 | 0 | 0 |
| Graft type, n (%) | ||||||
| Bone marrow | 26 (23) | 3 (11) | 6 (15) | 11 (18) | 7 (15) | 27 (20) |
| Peripheral blood | 63 (56) | 18 (64) | 29 (71) | 43 (69) | 32 (68) | 86 (63) |
| Cord blood | 23 (21) | 7 (25) | 6 (15) | 8 (13) | 8 (17) | 23 (17) |
| Year of transplant, n (%) | ||||||
| 2007 | 9 (8) | 5 (18) | 4 (10) | 6 (10) | 6 (13) | 9 (7) |
| 2008 | 14 (13) | 3 (11) | 9 (22) | 7 (11) | 6 (13) | 18 (13) |
| 2009 | 13 (12) | 7 (25) | 5 (12) | 6 (10) | 7 (15) | 18 (13) |
| 2010 | 13 (12) | 2 (7) | 4 (10) | 10 (16) | 6 (13) | 25 (18) |
| 2011 | 6 (5) | 1 (4) | 2 (5) | 1 (2) | 1 (2) | 5 (4) |
| 2012 | 5 (4) | 1 (4) | 3 (7) | 4 (6) | 2 (4) | 7 (5) |
| 2013 | 9 (8) | 3 (11) | 1 (2) | 7 (11) | 4 (9) | 18 (13) |
| 2014 | 23 (21) | 1 (4) | 4 (10) | 9 (15) | 8 (17) | 11 (8) |
| 2015 | 11 (10) | 2 (7) | 2 (5) | 7 (11) | 5 (11) | 11 (8) |
| 2016 | 9 (8) | 3 (11) | 7 (17) | 5 (8) | 2 (4) | 14 (10) |
| Follow-up, median (min-max) | 49.24 (6.12-126.41) | 52.57 (3.36-100.07) | 55.89 (3.42-90) | 47.4 (3.32-99.28) | 71.45 (3.49-97.86) | 48.19 (5.92-116.18) |
ATG, anti-thymocyte globulin; CSA, cyclosporine; NA, not available; HD, Hodgkin disease; NHL, non-Hodgkin lymphoma; Post tx-cy, Post-transplant cyclophosphamide.